SCHEMBL5759747

SCHEMBL5759747

O=c1cc(C(F)(F)F)c2cc(Cc3ccc(S(=O)(=O)NC4CCC(O)CC4)cc3)ccc2o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
MCL1 Q07820 1/20 0.37
ALDH1A1 P00352 2/20 0.37
AR P10275 8/20 0.36
HSD17B3 P37058 1/20 0.36
NAMPT P43490 1/20 0.35
PIK3CD O00329 2/20 0.35
PIK3CB P42338 2/20 0.35
PIK3CG P48736 2/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
HPGD P15428 2/20 0.35
CYP1A2 P05177 2/20 0.35
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
TLR9 Q9NR96 1/20 0.35
PGR P06401 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5860258 0.91 SMN1; SMN2 (0.44) TDP1ALDH1A1ARKDM4EHPGD
SCHEMBL5860196 0.90 ALDH1A1 (0.44) TDP1ALDH1A1KDM4EHPGDLMNA
SCHEMBL5759681 0.83 MAOB (0.53) KMT2AALDH1A1MEN1
SCHEMBL6105502 0.82 NAMPT (0.41) KMT2AMCL1ALDH1A1ARHSD17B3
SCHEMBL5762163 0.81 SCN9A (0.38) KMT2ATDP1MCL1ALDH1A1AR
SCHEMBL5762299 0.80 HDAC4 (0.46) KMT2AALDH1A1ARMEN1LMNA
SCHEMBL5760140 0.79 MCL1 (0.47) KMT2AMCL1ALDH1A1ARHSD17B3
SCHEMBL5762790 0.79 ALDH1A1 (0.44) KMT2ATDP1ALDH1A1ARKDM4E
SCHEMBL5860039 0.78 PKM (0.43) KMT2ATDP1MCL1ALDH1A1AR
SCHEMBL5761750 0.77 KDM4E (0.46) KMT2ATDP1ALDH1A1ARKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT KMT2A 816/4885TDP1 3413/4885MCL1 4501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.